Welcome to our dedicated page for Esperion Therape SEC filings (Ticker: ESPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Esperion Therapeutics filings document the regulatory record of a commercial-stage biopharmaceutical company focused on LDL-C lowering, cardiovascular-risk therapies, and related cardiometabolic programs. Its Form 8-K reports cover operating and financial results, clinical or regulatory disclosures, material agreements, capital-structure matters, and material-event updates tied to its commercial portfolio and development activities.
Esperion's SEC record also includes proxy disclosures on shareholder voting, board governance, executive compensation, equity awards, and pay-versus-performance information. Recent filings describe common stock registered on Nasdaq under ESPR, term-loan and credit-agreement amendments, acquisition-related financing, commercial leadership appointments, and other governance and compensation arrangements.
Esperion Therapeutics filed an amended current report to add detailed financial information for its acquisition of Corstasis Therapeutics, which closed on April 2, 2026. The deal is treated as an asset acquisition, with total cost of $83.389 million allocated mainly to Enbumyst, a developed product intangible valued at $77.097 million and amortized over 10 years.
The company funded the purchase with $75.0 million of new financing, including a $25.0 million term loan at 9.75% interest and a $50.0 million royalty sale tied to Otsuka payments until a $100.0 million cap is reached. Pro forma 2025 results show a combined net loss of $47.063 million, compared with Esperion’s standalone net loss of $22.682 million, reflecting added amortization and interest costs.
ESPR reported a Form 144 notice indicating 53,588 shares of Common Stock were listed for sale tied to restricted stock vesting on 06/16/2026 and designated as compensation. The filing also discloses a prior sale of 25,578 shares on 03/17/2026 for $69,551.70.
Benjamin Halladay filed a Form 144 reporting an intended resale of 10,773 shares of Common Stock tied to a restricted stock vesting event dated 06/15/2026. The filing also discloses 6,424 shares were sold on 03/17/2026.
ESPR submitted a Form 144 notice reporting a proposed sale of 11,824 shares of Common Stock tied to Restricted Stock Vesting, with an issuer designation dated 06/15/2026. The filing also records prior dispositions of 5,708 shares on 03/17/2026 for $15,427.58.
Esperion Therapeutics, Inc. reports that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its planned merger with Essence Parent Inc., an affiliate of ArchiMed SAS, expired at 11:59 p.m. Eastern Time on June 15, 2026.
The merger would make Esperion a wholly owned subsidiary of Essence Parent Inc. Completion still depends on other customary closing conditions in the Merger Agreement, including stockholder approval. A special virtual stockholder meeting to consider adoption of the Merger Agreement is scheduled for July 8, 2026 at 8:00 a.m. Eastern Time.
Esperion Therapeutics announced that Germany’s competition authority, the Bundeskartellamt, has cleared its planned merger with Essence Parent Inc., an affiliate of ArchiMed SAS. This removes a key regulatory condition under the German Act Against Restraints of Competition.
The merger would combine Esperion and Essence MergerCo Inc., with Esperion surviving as a wholly owned subsidiary of Parent. Completion still depends on remaining conditions, including expiration or termination of waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and approval of the merger agreement by Esperion stockholders at a virtual special meeting scheduled for July 8, 2026.
Esperion Therapeutics reported a Schedule 13G disclosing that Glazer Capital, LLC and Paul J. Glazer hold 20,975,620 shares, representing 8.15% of common stock.
The filing states the shares are held by Glazer-managed funds with shared voting and dispositive power of 20,975,620 shares. The filing lists Glazer Capital Enhanced Master Fund, Ltd. as a holder with the right to receive proceeds. Signatures are dated 06/08/2026.
Esperion Therapeutics has entered into an Agreement and Plan of Merger with Essence Parent Inc. and MergerCo, announced May 1, 2026, under which Esperion will become a wholly owned subsidiary if the merger closes. Each share will receive $3.16 in cash plus one contractual Contingent Value Right (CVR).
The Board unanimously recommends stockholder approval at a virtual special meeting on July 8, 2026. The record date for voting was May 28, 2026, when 257,693,347 shares were outstanding. The transaction is subject to antitrust clearance, other customary conditions, and the majority vote of outstanding shares.
THOMPSON JOHN CRAIG reported acquisition or exercise transactions in this Form 4 filing.
Esperion Therapeutics director John Craig Thompson received an equity award of 79,873 shares of common stock as compensation. The award was granted at no cash cost per share and represents his entire reported direct holding after the transaction. These shares vest in full on the earlier of May 28, 2027 or the company’s next annual meeting of stockholders following May 28, 2026.
Esperion Therapeutics director Jay Shepard reported an equity award of 79,873 shares of Common Stock. The shares were granted at no purchase price as a stock award and increase his direct holdings to 164,472 shares after the transaction.
The award vests in full on the earlier of May 28, 2027, or the company’s next annual meeting of stockholders following May 28, 2026, aligning vesting with future board service. This filing reflects compensation-related share acquisition rather than an open-market purchase or sale.